Previous 10 | Next 10 |
At the beginning of this year, Sorrento Therapeutics (NASDAQ: SRNE) was focused on its pain management drug, resiniferatoxin, as well as its Dimeric Antigen Receptor-T (DAR-T) cell therapy targeting various blood cancers and solid tumors. But the biotech has made a major piv...
Sorrento Therapeutics (SRNE) inks an agreement with ViralClear Pharmaceuticals, parent of BioSig Technologies (BSGM), aimed at exploring the potential of small molecule and antibody combination therapies in COVID-19.SRNE will initially contribute neutralizing antibody STI-1400 while ViralClea...
Sorrento to initiate testing with a selection of its agents in combination with ViralClear’s anti-viral compound for possible synergistic anti-viral effect against SARS-CoV-2 in the preclinical model of Golden Syrian hamster. ViralClear to contribute its oral antiviral Merime...
Shares of Sorrento Therapeutics (NASDAQ: SRNE) were surging 10.5% higher as of 11:07 a.m. EDT on Tuesday. The nice gain came following the company's announcement late Monday evening of encouraging preclinical data for its experimental COVID-19 antibody therapies STI-1499 and STI-202...
U.S. Energy (USEG) +168% after entering producing assets purchase agreement.Houston American Energy (HUSA) +77%.PEDEVCO (PED) +56%.Greenpro Capital Corp. (GRNQ) +53%.Flux Power Holdings (FLUX) +36% on FY results.Mexco Energy (MXC) +33%.Westwater Resources (WWR) +30%.New Co...
Sorrento Therapeutics (SRNE) shares up 6% in premarket, in reaction to preclinical data on COVI-GUARD (STI-1499) and COVI-AMG (STI-2020) antibodies against SARS-CoV-2, and both demonstrated neutralizing activities against SARS-CoV-2 virus infection.In May, it announced that STI...
In preclinical studies, both STI-1499 and STI-2020 demonstrated potent neutralizing activity against SARS-CoV-2 virus isolates, including the emerging Spike D614G variant virus. Both STI-1499 and STI-2020 demonstrated protective activities against SARS-CoV-2 infection in Syrian gold...
Sorrento ([[SRNE]] +7.3%) reports positive results from a Phase 1b clinical trial evaluating resiniferatoxin ((RTX)) in patients with moderate-to-severe pain due to osteoarthritis of the knee.98.8% (n=83/84) of patients experienced a treatment-emergent adverse event ((TEAE)) but only 6% ...
Phase 1b safety data at 6 month post-administration and Day 84 efficacy data available for all patients enrolled. No dose limiting toxicities at any of the doses tested (up to 30 ug) at 6 months post-administration. The study is scheduled to complete the last patient follow-up (1 ye...
Seventeen subjects with advanced cancer pain received epidural RTX (0.4 to 25 mcg). No dose limiting toxicities were reported, and a majority of patients reported meaningful pain reduction of 30% or more vs. baseline.Sorrento (SRNE) expects to immediately submit to the FDA a request to procee...
News, Short Squeeze, Breakout and More Instantly...
Sorrento Therapeutics Inc. Company Name:
SRNE Stock Symbol:
NASDAQ Market:
Sorrento Therapeutics Inc. Website:
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...
Smart Share Global Limited (EM) is expected to report for Q1 2024 American Rebel Holdings Inc. (AREB) is expected to report for Q1 2024 First Republic Bank (San Francisco, California) (FRCB) is expected to report for Q1 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ...